ICP-332 Tablets
DrugICP-332 will be administered as tablet
NCT Number: NCT06775860
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 3
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ICP-332 will be administered as tablet
ICP-332 Placebo will be administered as tablet
Time frame: 16 weeks
Time frame: 16 weeks
Contact information is provided by the study sponsor or research team.
Beijing InnoCare Pharma Tech Co., Ltd.
Industry
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of Oral ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07262983
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT04419584
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT07467564
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Doha, Qatar
View Trial DetailsNCT07216027
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Northridge, California, United States
View Trial Details